The rate of axillary lymph node response after NAC depends on tumor subtype, and the pathologic complete response (pCR) varies between 16% in hormonal receptor-positive HER-2-negative breast cancer, 70% in triple-negative breast cancer, and up to 80% in HER-2-positive breast cancer [4]. This evidence concerns the gene ERBB2 and breast carcinoma.